Literature DB >> 17374499

Plasma serotonin levels are normal in pulmonary arterial hypertension.

David J Lederer1, Evelyn M Horn, Erika B Rosenzweig, Wahida Karmally, Megan Jahnes, Robyn J Barst, Steven M Kawut.   

Abstract

Serotonin (5-HT) has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We hypothesized that plasma 5-HT would be elevated in PAH related to associated conditions. We performed a prospective cohort study of 21 patients with PAH undergoing initial right heart catheterization and 6 healthy controls. Platelet-free plasma 5-HT levels were similar in patients with idiopathic PAH, PAH related to associated conditions, and healthy controls. Higher 5-HT levels correlated with increased six-minute walk distance (r=0.55, p=0.04). These data suggest that plasma 5-HT levels are normal in PAH. Plasma 5-HT may therefore not be a useful biomarker in this condition.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17374499      PMCID： PMC2267916          DOI： 10.1016/j.pupt.2007.01.003

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN： 1094-5539            Impact factor:   3.410


  12 in total

1.  Estimation of plasma serotonin using isopycnic centrifugation.

Authors:  Harm J. Gijsman; Robbert-Jan Verkes; Jolanda C. M. Schouten-Verhagen; Rik C. Schoemaker; Joop M. A. Van Gerven; Roel H. De Rijk; Godfried M. J. Van Kempen
Journal:  Hum Psychopharmacol       Date:  2000-08       Impact factor: 1.672

2.  Genetic association of the serotonin transporter in pulmonary arterial hypertension.

Authors:  Rajiv D Machado; Rolf Koehler; Eric Glissmeyer; Colin Veal; Jay Suntharalingam; Miryoung Kim; John Carlquist; Margaret Town; C Gregory Elliott; Marius Hoeper; Anna Fijalkowska; Marcin Kurzyna; Jennifer R Thomson; Simon R Gibbs; Martin R Wilkins; Werner Seeger; Nicholas W Morrell; Ekkehard Gruenig; Richard C Trembath; Bart Janssen
Journal:  Am J Respir Crit Care Med       Date:  2006-01-06       Impact factor: 21.405

3.  Increased levels of free serotonin in plasma of symptomatic asthmatic patients.

Authors:  F Lechin; B van der Dijs; B Orozco; M Lechin; A E Lechin
Journal:  Ann Allergy Asthma Immunol       Date:  1996-09       Impact factor: 6.347

4.  Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension.

Authors:  Elisabeth D Willers; John H Newman; James E Loyd; Ivan M Robbins; Lisa A Wheeler; Melissa A Prince; Krista C Stanton; Joy A Cogan; James R Runo; Daniel Byrne; Marc Humbert; Gerald Simonneau; Benjamin Sztrymf; Jane A Morse; James A Knowles; Kari E Roberts; Jude J McElroy; Robyn J Barst; John A Phillips
Journal:  Am J Respir Crit Care Med       Date:  2005-12-09       Impact factor: 21.405

5.  Long-term serotonin administration induces heart valve disease in rats.

Authors:  Björn I Gustafsson; Karin Tømmerås; Ivar Nordrum; Jan P Loennechen; Anders Brunsvik; Erik Solligård; Reidar Fossmark; Ingunn Bakke; Unni Syversen; Helge Waldum
Journal:  Circulation       Date:  2005-03-21       Impact factor: 29.690

6.  Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia.

Authors:  Saadia Eddahibi; Christophe Guignabert; Anne-Marie Barlier-Mur; Laurence Dewachter; Elie Fadel; Philippe Dartevelle; Marc Humbert; Gerald Simonneau; Naïma Hanoun; Françoise Saurini; Michel Hamon; Serge Adnot
Journal:  Circulation       Date:  2006-04-10       Impact factor: 29.690

7.  Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.

Authors:  R B Rothman; J B Redmon; S K Raatz; C A Kwong; J E Swanson; J P Bantle
Journal:  Am J Cardiol       Date:  2000-04-01       Impact factor: 2.778

8.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

Authors:  S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

9.  Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.

Authors:  Steven M Kawut; Evelyn M Horn; Ketevan K Berekashvili; David J Lederer; Allison C Widlitz; Erika B Rosenzweig; Robyn J Barst
Journal:  Pulm Pharmacol Ther       Date:  2006-02-17       Impact factor: 3.410

10.  Increased plasma serotonin in primary pulmonary hypertension.

Authors:  P Hervé; J M Launay; M L Scrobohaci; F Brenot; G Simonneau; P Petitpretz; P Poubeau; J Cerrina; P Duroux; L Drouet
Journal:  Am J Med       Date:  1995-09       Impact factor: 4.965
View more
  8 in total

1.  Serotonin transporter polymorphisms in patients with portopulmonary hypertension.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Raymond L Benza; James A Knowles; David B Badesch; Robert S Brown; Darren B Taichman; James Trotter; Steven Zacks; Evelyn M Horn; Steven M Kawut
Journal:  Chest       Date:  2009-01-13       Impact factor: 9.410

2.  Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension.

Authors:  Gregory D Lewis; Debby Ngo; Anna R Hemnes; Laurie Farrell; Carly Domos; Paul P Pappagianopoulos; Bishnu P Dhakal; Amanda Souza; Xu Shi; Meredith E Pugh; Arkadi Beloiartsev; Sumita Sinha; Clary B Clish; Robert E Gerszten
Journal:  J Am Coll Cardiol       Date:  2016-01-19       Impact factor: 24.094

3.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

4.  Selective serotonin reuptake inhibitor use is associated with right ventricular structure and function: the MESA-right ventricle study.

Authors:  Corey E Ventetuolo; R Graham Barr; David A Bluemke; Aditya Jain; Joseph A C Delaney; W Gregory Hundley; Joao A C Lima; Steven M Kawut
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

5.  The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series).

Authors:  Margaret Mandy R MacLean
Journal:  Pulm Circ       Date:  2018 Apr-Jun       Impact factor: 3.017

6.  Comparison of pre-analytical conditions for quantification of serotonin in platelet-poor plasma.

Authors:  Hilde L Von Volkmann; Ingeborg Brønstad; Torunn Fiskerstrand; Oddrun Anita Gudbrandsen
Journal:  Pract Lab Med       Date:  2019-09-19

Review 7.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

8.  Serotonin-deficient neonatal mice are not protected against the development of experimental bronchopulmonary dysplasia or pulmonary hypertension.

Authors:  Danielle S Roberts; Laura G Sherlock; Janelle N Posey; Jamie L Archambault; Eva S Nozik; Cassidy A Delaney
Journal:  Physiol Rep       Date:  2022-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.